A pathogenetic role for M1 macrophages in peritoneal dialysis-associated fibrosis

Qing Li1, Min Zheng1, Yueheng Liu2

  • 1Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.

Molecular Immunology
|January 7, 2018
PubMed

Insights

Depleting macrophages significantly reduced peritoneal fibrosis (PF) in a mouse model of peritoneal dialysis (PD). M1 macrophages exacerbated PF, while M2 macrophages showed protective effects, highlighting distinct roles in disease progression.

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Peritoneal fibrosis (PF) is a serious complication of peritoneal dialysis (PD), characterized by inflammatory cell infiltration.
  • The specific roles of different macrophage phenotypes in the inflammatory microenvironment of PD-induced PF are not well understood.

Purpose of the Study:

  • To investigate the role of distinct macrophage phenotypes in the progression of peritoneal fibrosis.
  • To elucidate the impact of macrophage depletion and repopulation with specific phenotypes on PF development in a mouse model.

Main Methods:

  • A mouse model of peritoneal dialysis was established using instilled PD fluids (PDFs).
  • Macrophage depletion was achieved using liposomal clodronate (LC).
  • Primary macrophages (M0) were differentiated into M1 and M2 phenotypes and adoptively transferred into mice.

Main Results:

  • Systemic macrophage depletion led to reduced structural alterations, extracellular matrix (ECM) deposition, and improved peritoneal ultrafiltration function.
  • Depletion decreased expression of alpha-smooth muscle actin (α-SMA) and fibronectin, while increasing E-cadherin expression.
  • Reperfusion with M1 macrophages significantly worsened histological damage, ECM deposition, and functional decline, with enhanced TLR4 expression, whereas M2 macrophages showed a less detrimental effect.

Conclusions:

  • Macrophages play a critical role in mediating peritoneal fibrosis during PD.
  • M1 macrophages are key mediators exacerbating PF, while M2 macrophages may have protective or less detrimental roles.
  • Targeting specific macrophage phenotypes presents a potential therapeutic strategy for managing peritoneal fibrosis in PD patients.

Related Concept Videos

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
928
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
3.7K
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
932
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
561
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.5K
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
1.9K